Ken Takanashi - Wave Life Corporate Secretary and Director
| WVE Stock | USD 5.01 0.07 1.38% |
Director
Mr. Ken Takanashi is Independent Director of the Company. Mr. Takanashi has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd., or SNBL, and its affiliates and currently serves as its Executive Vice President, Chief Operating Officer. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014 since 2012.
| Age | 54 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Address | Marina One East Tower, Singapore, Singapore, 018936 |
| Phone | 65 6236 3388 |
| Web | https://www.wavelifesciences.com |
Ken Takanashi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ken Takanashi against Wave Life stock is an integral part of due diligence when investing in Wave Life. Ken Takanashi insider activity provides valuable insight into whether Wave Life is net buyers or sellers over its current business cycle. Note, Wave Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Wave Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ken Takanashi over six months ago Acquisition by Ken Takanashi of 45000 shares of Wave Life subject to Rule 16b-3 |
Wave Life Management Efficiency
The company has Return on Asset of (0.2017) % which means that on every $100 spent on assets, it lost $0.2017. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (11.1817) %, meaning that it generated no profit with money invested by stockholders. Wave Life's management efficiency ratios could be used to measure how well Wave Life manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.81. At present, Wave Life's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 3.33, whereas Other Assets are forecasted to decline to about 4.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Deborah McAneny | Tscan Therapeutics | 58 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| Mauro Ferrari | Arrowhead Pharmaceuticals | 58 | |
| Michael Bonney | Alnylam Pharmaceuticals | 59 | |
| James Meyers | CytomX Therapeutics | 54 | |
| Richard Jones | Mereo BioPharma Group | 50 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Dennis Ausiello | Alnylam Pharmaceuticals | 72 | |
| Elaine Jones | CytomX Therapeutics | 60 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Anders Ekblom | Mereo BioPharma Group | 63 | |
| Michael Wyzga | Mereo BioPharma Group | 63 | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Peter Bains | Mereo BioPharma Group | 61 | |
Management Performance
| Return On Equity | -11.18 | ||||
| Return On Asset | -0.2 |
Wave Life Sciences Leadership Team
Elected by the shareholders, the Wave Life's board of directors comprises two types of representatives: Wave Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wave. The board's role is to monitor Wave Life's management team and ensure that shareholders' interests are well served. Wave Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wave Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Verdine, Independent Chairman of the Board | ||
| Masaharu Tanaka, Independent Director | ||
| Kate Rausch, Investor Relations | ||
| Stephen Lake, VP Devel | ||
| Linda JD, Senior Counsel | ||
| Michael Panzara, Franchise Lead, Neurology | ||
| Adrian Rawcliffe, Independent Director | ||
| MBA MD, CEO Pres | ||
| Kyle CFA, CFO Officer | ||
| Roberto MD, Head of Early Devel. and Sr. VP | ||
| Takeshi Wada, Independent Director | ||
| AnneMarie LiKwaiCheung, Chief Officer | ||
| Peter Kolchinsky, Independent Director | ||
| Chandra Vargeese, Head of Drug Discovery and Sr. VP | ||
| Ken Takanashi, Corporate Secretary and Director | ||
| Christian Henry, Additional Independent Director | ||
| Sridhar Vaddeboina, Manufacturing Chemistry | ||
| HsiuChiung Yang, Senior Medicine | ||
| Koji Miura, Independent Director | ||
| MD MBA, CEO President | ||
| Daryn Lewis, Senior Resources | ||
| Paul Bolno, President CEO, Director | ||
| Keith Regnante, CFO and Principal Accounting Officer | ||
| Graham Morrell, IR Contact Officer | ||
| Kyle Moran, Head of Fin. and VP | ||
| Roberto Guerciolini, Senior Vice President Head of Early Development | ||
| Jonathan Rosin, Chief Officer | ||
| Christopher Francis, Head of Bus. Devel. and VP |
Wave Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Wave Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.18 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 460.84 M | ||||
| Shares Outstanding | 122.28 M | ||||
| Shares Owned By Insiders | 18.20 % | ||||
| Shares Owned By Institutions | 74.79 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (6.50) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Wave Life Sciences is a strong investment it is important to analyze Wave Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Wave Life's future performance. For an informed investment choice regarding Wave Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Wave Stock analysis
When running Wave Life's price analysis, check to measure Wave Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Wave Life is operating at the current time. Most of Wave Life's value examination focuses on studying past and present price action to predict the probability of Wave Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Wave Life's price. Additionally, you may evaluate how the addition of Wave Life to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Wave Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Wave Life. If investors know Wave will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Wave Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.068 | Quarterly Revenue Growth 22.451 | Return On Assets (0.20) | Return On Equity (11.18) |
The market value of Wave Life Sciences is measured differently than its book value, which is the value of Wave that is recorded on the company's balance sheet. Investors also form their own opinion of Wave Life's value that differs from its market value or its book value, called intrinsic value, which is Wave Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Wave Life's market value can be influenced by many factors that don't directly affect Wave Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Wave Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Wave Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Wave Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.